VRTX Jan 2025 330.000 call
- Insider Monkey
Jim Simons Stock Portfolio: 10 Top Stock Picks
In this article, we discuss Jim Simons and his top 10 stock picks. If you want to read about some more stocks in the Simons portfolio, go directly to Jim Simons Stock Portfolio: 5 Top Stock Picks. In June this year, Stony Brook University, a public college in New York, saw the endowment fund it […]
- Motley Fool
This Newly Discovered Risk Could Be a Big Headache for Vertex Pharmaceuticals and CRISPR Therapeutics
In the gene editing therapies space, there aren't any competitors being watched more closely than Vertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP). The pair scored regulatory approval in the U.K. on Nov. 16 to market their first gene therapy developed in collaboration and investors have high hopes for a positive commercialization decision by the Food and Drug Administration (FDA) in the U.S. on Friday, Dec. 8. The gene therapy candidate made by Vertex and CRISPR Therapeutics is called exa-cel, and it's intended to treat sickle cell disease (SCD), a hereditary blood disorder that causes red blood cells to have a shape that's closer to a waxing crescent moon than their proper and iconic frisbee-like form.
- Motley Fool
5 Unstoppable Trends to Invest $1,000 in for 2024
These next-big-thing trends represent some of the most exciting moneymaking opportunities for investors next year.
